Research

Hormonal

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

StrongSupportsVERY_HIGH confidence
Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events.
Darren K. McGuire et al. · New England Journal of Medicine · 2025

Why this rating

The study is a large, double-blind, placebo-controlled, event-driven superiority trial (SOUL) with 9650 participants, published in the New England Journal of Medicine.

Source

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Darren K. McGuire et al. · New England Journal of Medicine · 2025

DOI 10.1056/nejmoa2501006

rct · n=9650Cited 274×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →